BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28032275)

  • 1. CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.
    Yokoyama M; Ichinoe M; Okina S; Sakurai Y; Nakada N; Yanagisawa N; Jiang SX; Numata Y; Umezawa A; Miyazaki K; Higashihara M; Murakumo Y
    Int J Hematol; 2017 May; 105(5):614-622. PubMed ID: 28032275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD109 release from the cell surface in human keratinocytes regulates TGF-β receptor expression, TGF-β signalling and STAT3 activation: relevance to psoriasis.
    Litvinov IV; Bizet AA; Binamer Y; Jones DA; Sasseville D; Philip A
    Exp Dermatol; 2011 Aug; 20(8):627-32. PubMed ID: 21539622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells.
    Zhang JM; Murakumo Y; Hagiwara S; Jiang P; Mii S; Kalyoncu E; Saito S; Suzuki C; Sakurai Y; Numata Y; Yamamoto T; Takahashi M
    Biochem Biophys Res Commun; 2015 Apr; 459(2):252-258. PubMed ID: 25724945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF-β signaling.
    Taki T; Shiraki Y; Enomoto A; Weng L; Chen C; Asai N; Murakumo Y; Yokoi K; Takahashi M; Mii S
    Cancer Sci; 2020 Dec; 111(12):4616-4628. PubMed ID: 33007133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function.
    Bizet AA; Tran-Khanh N; Saksena A; Liu K; Buschmann MD; Philip A
    J Cell Biochem; 2012 Jan; 113(1):238-46. PubMed ID: 21898545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.
    Hagiwara S; Murakumo Y; Mii S; Shigetomi T; Yamamoto N; Furue H; Ueda M; Takahashi M
    Oncogene; 2010 Apr; 29(15):2181-91. PubMed ID: 20101215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of down-regulation of CD109 expression with up-expression of Smad7 in pathogenesis of psoriasis.
    Liu XX; Feng AP; He YM; Li Y; Wu Y; Lian X; Hu F; Li JW; Tu YT; Chen SJ
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):132-136. PubMed ID: 26838754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder.
    Dong F; Lu C; Chen X; Guo Y; Liu J
    Diagn Pathol; 2015 Aug; 10():137. PubMed ID: 26249215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma.
    Ye BG; Sun HC; Zhu XD; Chai ZT; Zhang YY; Ao JY; Cai H; Ma DN; Wang CH; Qin CD; Gao DM; Tang ZY
    Oncotarget; 2016 May; 7(20):29333-45. PubMed ID: 27121053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble CD109 binds TGF-β and antagonizes TGF-β signalling and responses.
    Li C; Hancock MA; Sehgal P; Zhou S; Reinhardt DP; Philip A
    Biochem J; 2016 Mar; 473(5):537-47. PubMed ID: 26621871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
    Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
    Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression.
    Hagikura M; Murakumo Y; Hasegawa M; Jijiwa M; Hagiwara S; Mii S; Hagikura S; Matsukawa Y; Yoshino Y; Hattori R; Wakai K; Nakamura S; Gotoh M; Takahashi M
    Pathol Int; 2010 Nov; 60(11):735-43. PubMed ID: 20946523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-β.
    Tanabe M; Hosokawa K; Nguyen MAT; Nakagawa N; Maruyama K; Tsuji N; Urushihara R; Espinoza L; Elbadry MI; Mohiuddin M; Katagiri T; Ono M; Fujiwara H; Chonabayashi K; Yoshida Y; Yamazaki H; Hirao A; Nakao S
    Leukemia; 2022 Mar; 36(3):847-855. PubMed ID: 34743190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of CD109 expression in myxofibrosarcoma.
    Emori M; Tsukahara T; Murata K; Sugita S; Sonoda T; Kaya M; Soma T; Sasaki M; Nagoya S; Hasegawa T; Wada T; Sato N; Yamashita T
    J Surg Oncol; 2015 Jun; 111(8):975-9. PubMed ID: 26031650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes.
    Finnson KW; Tam BY; Liu K; Marcoux A; Lepage P; Roy S; Bizet AA; Philip A
    FASEB J; 2006 Jul; 20(9):1525-7. PubMed ID: 16754747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors.
    Bizet AA; Liu K; Tran-Khanh N; Saksena A; Vorstenbosch J; Finnson KW; Buschmann MD; Philip A
    Biochim Biophys Acta; 2011 May; 1813(5):742-53. PubMed ID: 21295082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of expression of CD109 in osteosarcoma and its involvement in tumor progression via BMP signaling.
    Mori N; Esaki N; Shimoyama Y; Shiraki Y; Asai N; Sakai T; Nishida Y; Takahashi M; Enomoto A; Mii S
    Pathol Res Pract; 2023 May; 245():154443. PubMed ID: 37030166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
    van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
    J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro.
    Zhou S; da Silva SD; Siegel PM; Philip A
    Sci Rep; 2019 Nov; 9(1):16317. PubMed ID: 31695056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.